Refine by
Interventional Cardiology Articles & Analysis
49 news found
The products of four hydrogel companies Sawhney founded with his partner Fred Khosravi (within their accelerator Incept LLC), have treated more than five million patients across the ophthalmic, surgical, interventional cardiology, and prostate cancer specialties. Sawhney founded Confluent Surgical in 1998, which, after proving out a hydrogel platform for ...
Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals. ...
A cardiac puzzle This procedure, like the one before it, was conducted with the assistance of Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, and EchoPixel’s chief medical officer. ...
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely ...
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). The data was presented during a Late-Breaking Clinical Trial session at the 2022 ...
Since the launch of the Sedakit™ for Digital Sedation in Benelux and France in June 2019, over 30,000 patients have been treated and have had their pain and anxiety relieved before, during, and after interventions in many clinical fields such as anesthesia, oncology, interventional radiology and cardiology, as well as pediatrics. ...
Montreal-based Puzzle Medical Devices Inc., announced today the successful completion of the company’s ?rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). Four patients had ModulHeart deployed to provide circulatory support while undergoing ...
Professor Jean-Benoît Thambo, head of the department of pediatric and congenital cardiology at the Bordeaux University Hospital, said to France3 how “these prostheses are the first phase of the medicine of tomorrow, a medicine that opts for material adapted to the body, biological”. As interventional cardiologist Zakaria Jalal explained to ...
Serruys is is a professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands (1988-1998), and Erasmus MC. ...
The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for Cardiovascular Angiography & Interventions (SCAI). Unlike previous reports with atherectomy that have shown worse angiographic complications in women versus men,i a pooled analysis of the Disrupt CAD III & IV studies showed that IVL was equally ...
It is now the only viable and long-term answer to procedures becoming increasingly long and complex and requiring high precision, expertise and experience in interventional cardiology. While it is revolutionary, the system uses the same devices as those currently used and is compatible with all imaging systems, which should make uptake easy among all ...
ByRobocath
The DSMB consists of two world renowned cardiologists with experience in heart failure and interventional cardiology, as well as a world-renowned biostatistician with considerable experience evaluating trial data for chronic diseases, including heart failure. ...
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives. At the 30-day follow up point, the first five patients of the planned 10-patient study showed: All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention). An average 86% improvement in mean ...
Van Der Ent; and the National Interventional Cardiac Surgery Institute in Luxembourg with Dr Pereira and Dr Muller. ...
ByRobocath
The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications. This robotic assisted procedure is the first intervention within a clinical study carried out by CathBot; a joint venture between Robocath and MedBot (the robot-focused ...
ByRobocath
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts associated with the use of its ...
BioCardia, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. These patients experience ...
The TCT conference, running from November 4 to 6, is the largest and most prestigious Interventional cardiology meeting held each year and will return to an “in-person” meeting format. ...
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the full approval of its Investigational Device Exemption (IDE) application by the FDA to conduct the pivotal STAR–D (Safe and Timely Antithrombotic Removal – Direct ...
Rather than relying on contrast dye and X-ray based imaging to help guide the implant placement, Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, performed the procedure using ultrasound-based 4D holographic imaging, which provides an image so clear that potentially harmful contrast dye ...